Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Applying for CDSCO...

    Applying for CDSCO license for your drug? Make Sure your formulation does not have similar brand name

    Farhat NasimWritten by Farhat Nasim Published On 2019-11-09T16:52:29+05:30  |  Updated On 16 Aug 2021 4:39 PM IST

    New Delhi: In a bid to curb the irrational practice of using similar names for different drugs that results in utter confusion, the Union Health Minister has recently laid conditions of seeking a licence for undertaking on brand or trade names of drugs under Drugs Rules, 1945, wherein, the drug makers will have to furnish an undertaking to the licensing authority to the effect that a similar brand name is not in existence and it would not lead to any confusion or deception in the market.


    In this regard, the Health Ministry had issued a draft notification proposing to amend the Drugs and Cosmetics Rules, 1945 to incorporate a provision for regulating brand names by the central licensing authority. The authority had invited objections and suggestions from stakeholders before the expiry of a period of forty-five days, which was made available to the public on February 27 2019.


    Suggestions were received and considered by the Central Government and now in exercise of the powers conferred under sections 12 and 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board (DTAB), hereby makes the following rules further to amend the Drugs and Cosmetics Rules, 1945, namely;


    In the Drugs and Cosmetics Rules, 1945 (hereinafter referred to as said rules), in rule 71, after subrule (8), the following sub-rule shall be inserted, namely;




    "(9) In case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation (CDSCO), literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.".



    In the said rules, in rule 71A, after sub-rule (4), before the proviso, the following sub-rule shall be inserted, namely:―

    "(5) In case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade-marks registry, central data-base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation (CDSCO), literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.".



    In the said rules, in rule 71B, after clause (iv), before the proviso, the following clause shall be inserted, namely:―

    "(v) in case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation (CDSCO), literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market:".



    In the said rules, in rule 76, after sub-rule (10), the following sub-rule shall be inserted, namely:―




    "(11) In case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation (CDSCO), literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.".



    In the said rules, in rule 76A, after clause (iv), before the proviso, the following clause shall be inserted, namely:―

    "(v) in case the applicant intends to market the drug under a brand name or trade name, the applicant shall furnish an undertaking in Form 51 to the licensing authority to the effect that to the best of his knowledge based on search in trade marks registry, central data base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation (CDSCO), literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market:".



    In the said rules, in Schedule A, after Form 50, the following Form shall be inserted, namely:―

    "FORM 51
    [See rules 71(9), 71A(5), 71B(v), 76(11) and 76A(v)]
    Form of undertaking to the licensing authority for marketing a drug under a brand name or trade name



    (1) I .............................. of............................. intend to market the drug specified below under a brand name or trade name - ……………………………
    (i) Name of the drug :
    (ii) Dosage form :
    (iii) Composition :


    (2) I hereby give this undertaking that to the best of my knowledge based on search in trade-marks registry, central data-base for brand name or trade name of drugs maintained by Central Drugs Standard Control Organisation, literature and reference books on details of drug formulations in India, and internet, such or similar brand name or trade name is not already in existence with respect to any drug in the country and the proposed brand name or trade name shall not lead to any confusion or deception in the market.
    Place………………..
    Date ………..............


    [Signature, Name, Designation Seal/Stamp of the manufacturer or on behalf of the manufacturer].".


    Also Read: ZENTEL VERSUS FENTEL: HC restrains manufacture, sale of medicine for violation of trademark
    brand namesbranded drugsCDSCOCentral Drugs Standard Control Organisationcentral govtdrugDrug Technical Advisory BoardDrugs and Cosmetics ActDTABgeneric drugshealthHealth Ministry

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok